Browse result page of AntiTbPdb
The total number entries retrieved from this search are 550
ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
antitb_1448 | A2-Rv2957 | SIIIPTLNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1449 | A2-Rv0447 | VLAGSVDEL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1450 | A24-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1451 | A24-Ag85B | WYYQSGLSI | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1452 | A24-Ag85B | FLTSELPQW | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1453 | A24-Ag85B | IYAGSLSAL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1454 | A24-ESAT6 | AYQGVQQKW | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1455 | A24-ESAT6 | ELNNALQNL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1456 | A24-Rv2958 | KYIAADRKI | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1457 | A24-Rv2957 | PYNLRYRVL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1458 | A24-Rv0447 | KYIFPGGLL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1459 | A3001-TB10.4 | QIMYNYPAM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1460 | A3001-TB10.4 | LVRAYHAMS | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1461 | A3001-Rv2957 | IVLVRRWPK | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2957 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2957 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1462 | A3002-TB10.4 | QIMYNYPAM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1463 | A3002-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1464 | A3002-TB10.4 | AMEDLVRAY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1465 | A3002-ESAT6 | AMASTEGNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1466 | A3002-Rv2958 | SARLAGIPY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1467 | A3002-Rv0447 | RMWELYLAY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1468 | A68-TB10.4 | HAMSSTHEA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1469 | A68-TB10.4 | ANTMAMMAR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1470 | A68-Ag85B | LPQWLSANR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1471 | A68-Ag85B | WGAQLNAMK | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1472 | A68-Rv2958 | AAPEPVARR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1473 | A68-Rv2957 | LVYGDVIMR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2957 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2957 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1474 | A68-Rv0447 | AASAAIANR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1475 | B58-Ag85B | QTYKWETFL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1476 | Cw07-Ag85B | ANNTRLWVY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
antitb_1478 | Lariatin A | GSQLVYRWVGHSNVIKGP | NA | NA | Alpha carbon of glutamine form amide bond with first glycine and gamma carbon of glutamine involved in side chain formation | Cyclic | 18 | D | Cationic | Natural | Derived from Rhodococcusjostii K01â€B0171 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | MIC = 0.39 mg/L | in vitro | NA | NA | NA | NA | NA | NA | Inhibit cell wall biosynthesis | NA | NA | NA | 2015 | 25681127 |
antitb_1479 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | IC50= 0.0125-25mg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
antitb_1480 | Dihydromycoplanecin A (DHMP A) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Actinoplanesawajinensis | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | IC90= 0.05 μg/mL | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 |
antitb_1486 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 25 mm at 100 μg conc. | LoVo cancer cells | NA | IC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1487 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 10 mm at 25 μg | LoVo cancer cells | NA | IC50= 2.25μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1488 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 15 mm at 100 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1489 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 9 mm at 25 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1490 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 30 mm at 100 μg | LoVo cancer cells | NA | IC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1491 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 25177 | Reduction in zone of growth to 15 mm at 25 μg | LoVo cancer cells | NA | IC50= 2.25μg/ml for M.Smegmatis ATCC 25177 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1492 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 15 mm at 100 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1493 | Pitipeptolides A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Cyanobacterium Lyngbya majuscula | Mycobacterium tuberculosis | Mycobacteria smegmatis ATCC 35818 | Reduction in zone of growth to 10 mm at 25 μg | LoVo cancer cells | NA | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 | NA | NA | NA | NA | NA | NA | NA | 2015 | 25681127 | |
antitb_1494 | Lacticin 3147 | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37 Ra | IC90= 7.5 mg/ml (±0.36) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
antitb_1495 | Lacticin 3148 | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium tuberculosis | Mycobacteria kansasii CIT11/06 | IC90= 60 mg/ml (±0.75) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
antitb_1497 | Nisin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcus lactis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37 Ra | IC90= >60mg/ml (±0.18) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
antitb_1498 | Nisin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Lactococcuslactis | Mycobacterium tuberculosis | Mycobacteria kansasii CIT11/06 | IC90= 60 mg/ml (±0.13) | in vitro | NA | NA | NA | NA | NA | NA | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane | NA | NA | NA | 2015 | 25681127 |
antitb_1500 | Sansanmycins A (Ssa) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Streptomyces species | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50= 16 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Inhibit the MraY translocase present in the bacterial cell membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 |
antitb_1501 | Sansanmycins A (Ssa) | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Streptomyces species | Mycobacterium tuberculosis | Mycobacterium tuberculosis 2199 | IC50= 32 μg/ml | In vitro | NA | NA | NA | NA | NA | NA | Inhibit the MraY translocase present in the bacterial cell membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 |
antitb_1502 | Cyclomarin A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Streptomyces species | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50= 0.3mg/ml | in vitro | NA | NA | NA | NA | NA | Change the clp1subunit of casinolytic protease by allosteric binding | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
antitb_1503 | Massetolide A | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Pseudomonas fluorescens SS101 | Mycobacterium tuberculosis | Mycobacterium tuberculosis h37RV | MIC = 5 mg/ml | in vitro | NA | NA | NA | NA | NA | interfere with bacterial cell wall biosynthesis | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
antitb_1504 | Visconsin | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Pseudomonas species | Mycobacterium tuberculosis | Mycobacterium avium intercellularae | MIC = 10 mg/ml | in vitro | NA | NA | NA | NA | NA | interfere with bacterial cell wall biosynthesis | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
antitb_1505 | Bacitracin | not available | NA | NA | NA | Branched cyclic | 0 | D | Cationic | Natural | Derived from Bacillus subtilis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 130mg/ml | in vitro | NA | NA | NA | NA | NA | NA | inhibit bacterial cell wall synthesis | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 |